BRPI0512944A - agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 - Google Patents
agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1Info
- Publication number
- BRPI0512944A BRPI0512944A BRPI0512944-3A BRPI0512944A BRPI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hmgb1
- therapeutic agents
- related conditions
- nucleic acid
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000055207 HMGB1 Human genes 0.000 abstract 1
- 108700010013 HMGB1 Proteins 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/52—Physical structure branched
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58467804P | 2004-07-02 | 2004-07-02 | |
| US64658605P | 2005-01-26 | 2005-01-26 | |
| PCT/EP2005/007198 WO2006002971A2 (en) | 2004-07-02 | 2005-07-04 | Nucleic acids for the treatment of hmgb1-related pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512944A true BRPI0512944A (pt) | 2008-04-15 |
Family
ID=35106975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512944-3A BRPI0512944A (pt) | 2004-07-02 | 2005-07-04 | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20080305073A1 (enExample) |
| EP (1) | EP1768677B1 (enExample) |
| JP (1) | JP2008504335A (enExample) |
| AT (1) | ATE399014T1 (enExample) |
| AU (1) | AU2005259381A1 (enExample) |
| BR (1) | BRPI0512944A (enExample) |
| CA (1) | CA2572519A1 (enExample) |
| DE (1) | DE602005007746D1 (enExample) |
| DK (1) | DK1768677T3 (enExample) |
| ES (1) | ES2306195T3 (enExample) |
| IL (1) | IL179828A0 (enExample) |
| PL (1) | PL1768677T3 (enExample) |
| PT (1) | PT1768677E (enExample) |
| WO (1) | WO2006002971A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101323411B1 (ko) | 2004-08-03 | 2013-10-30 | 트랜스테크 파르마, 인크. | Ｒａｇｅ 융합 단백질 및 이의 사용 방법 |
| US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
| EP1989227A2 (en) * | 2006-02-09 | 2008-11-12 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| JP3882090B1 (ja) * | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
| KR20090087483A (ko) * | 2006-11-17 | 2009-08-17 | 클리니컬 진 네트웍스 아베 | 유전자 ｇｙｐｃ, ａｇｐａｔ3, ａｇｌ, ｐｖｒｌ2, ｈｍｇｂ3, ｈｓｄｌ2 및/또는 ｌｄｂ2를 포함하는 스크리닝 및 치료방법 |
| CN101589309A (zh) * | 2006-11-17 | 2009-11-25 | 临床基因网络公司 | 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法 |
| WO2009140676A2 (en) * | 2008-05-16 | 2009-11-19 | Immune Disease Institute, Inc. | Compositions and methods for inhibition of retroviruses |
| US8710021B2 (en) | 2008-06-11 | 2014-04-29 | Bionucleon S.R.L. | Inhibition of HRP-3 using modified oligonucleotides |
| BRPI0916349A2 (pt) | 2008-09-11 | 2019-09-24 | Pasteur Institut | monitoramento e inibição da infecção pelo vírus da imunodeficiência humana através da modulação do desencadeamento dependete de hmgb1 da replicação e persistência do hiv-1 |
| US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
| KR101431165B1 (ko) | 2008-12-22 | 2014-08-18 | 크레아빌리스 에스.에이. | 인돌로카르바졸 화합물의 중합체 컨쥬케이트의 합성 |
| RU2011142230A (ru) | 2009-04-20 | 2013-05-27 | Пфайзер Инк. | Контроль гликозилирования белка и композиции и способы, касающиеся этого |
| GB0911569D0 (en) * | 2009-07-03 | 2009-08-12 | Ulive Entpr Ltd | Method for the detection of organ or tissue injury |
| JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
| US8975019B2 (en) * | 2009-10-19 | 2015-03-10 | University Of Massachusetts | Deducing exon connectivity by RNA-templated DNA ligation/sequencing |
| CN103096899B (zh) | 2010-09-17 | 2015-01-28 | 独立行政法人科学技术振兴机构 | 由 hmgb 蛋白介导的免疫应答激活的抑制剂及筛选方法 |
| WO2013116590A1 (en) * | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| JP6624542B2 (ja) * | 2015-02-05 | 2019-12-25 | 国立大学法人広島大学 | ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置 |
| WO2018175301A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugate of montesanib with reduced exposure |
| WO2018175315A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates of staurosporine derivatives having reduced exposure |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| EP3621657A1 (en) | 2017-05-10 | 2020-03-18 | Sienna Biopharmaceuticals, Inc. | Uses of polymer conjugates of indolocarbazole compounds with reduced exposure |
| CN111304202B (zh) * | 2020-02-26 | 2023-03-28 | 西安交通大学 | 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用 |
| CN114957440A (zh) * | 2022-05-26 | 2022-08-30 | 江苏大学 | 一种重组HMGB1 A Box蛋白及其获取方法与应用 |
| US20250262230A1 (en) * | 2022-06-23 | 2025-08-21 | The Regents Of The University Of California | HMGB1 Inhibitors for Treatment of APOE4-related Tauopathies including Alzheimer’s Disease |
| CN114807150B (zh) * | 2022-06-28 | 2022-10-14 | 中国科学院基础医学与肿瘤研究所(筹) | 靶向和拮抗hmgb1分子的核酸适体 |
| JP2025525583A (ja) | 2022-07-19 | 2025-08-05 | ランパート バイオサイエンス インコーポレイテッド | 非免疫原性環状非ウイルス性ｄｎａベクター |
| CN115774004B (zh) * | 2022-08-19 | 2024-07-05 | 四川大学华西医院 | 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5442194A (en) * | 1992-10-14 | 1994-05-09 | University Research Corporation | Method for selecting nucleic acids on the basis of structure |
| ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
| NZ540067A (en) * | 2002-11-20 | 2007-05-31 | Critical Therapeutics Inc | A purified preparation of antibodies that specifically bind to a high mobility group box protein (HMGB) B box but do not specifically to non-B box epitopes of HMGB |
-
2005
- 2005-07-04 US US11/631,328 patent/US20080305073A1/en not_active Abandoned
- 2005-07-04 DK DK05773148T patent/DK1768677T3/da active
- 2005-07-04 JP JP2007518555A patent/JP2008504335A/ja active Pending
- 2005-07-04 WO PCT/EP2005/007198 patent/WO2006002971A2/en not_active Ceased
- 2005-07-04 CA CA002572519A patent/CA2572519A1/en not_active Abandoned
- 2005-07-04 ES ES05773148T patent/ES2306195T3/es not_active Expired - Lifetime
- 2005-07-04 AT AT05773148T patent/ATE399014T1/de not_active IP Right Cessation
- 2005-07-04 AU AU2005259381A patent/AU2005259381A1/en not_active Abandoned
- 2005-07-04 BR BRPI0512944-3A patent/BRPI0512944A/pt not_active IP Right Cessation
- 2005-07-04 PL PL05773148T patent/PL1768677T3/pl unknown
- 2005-07-04 DE DE602005007746T patent/DE602005007746D1/de not_active Revoked
- 2005-07-04 EP EP05773148A patent/EP1768677B1/en not_active Revoked
- 2005-07-04 PT PT05773148T patent/PT1768677E/pt unknown
-
2006
- 2006-12-04 IL IL179828A patent/IL179828A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1768677T3 (pl) | 2009-01-30 |
| ATE399014T1 (de) | 2008-07-15 |
| CA2572519A1 (en) | 2006-01-12 |
| JP2008504335A (ja) | 2008-02-14 |
| WO2006002971A3 (en) | 2006-04-20 |
| AU2005259381A1 (en) | 2006-01-12 |
| WO2006002971A2 (en) | 2006-01-12 |
| DE602005007746D1 (de) | 2008-08-07 |
| US20080305073A1 (en) | 2008-12-11 |
| EP1768677B1 (en) | 2008-06-25 |
| EP1768677A2 (en) | 2007-04-04 |
| DK1768677T3 (da) | 2008-10-20 |
| ES2306195T3 (es) | 2008-11-01 |
| IL179828A0 (en) | 2008-03-20 |
| PT1768677E (pt) | 2008-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0512944A (pt) | agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| DE602006019838D1 (de) | Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten | |
| ATE499088T1 (de) | Glp-1-fc fusionsprotein-formulierung | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
| EA200702358A1 (ru) | Комбинация ингибитора pde4 и производного тетрагидробиоптерина | |
| CY1114965T1 (el) | Cpg ολιγονουκλεοτιδια χρησιμοποιουμενα για ενισχυση της δραστικοτητας στεροειδων σε εναν εξαρτημενο απο στεροειδη ασθενη | |
| EA201370208A1 (ru) | Формы рифаксимина и их применение | |
| EP1957413A4 (en) | Sewage treatment | |
| ATE429218T1 (de) | Pinolensäure zur behandlung von übergewicht | |
| EA201100297A1 (ru) | Биотесты на белок polyq | |
| BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| ATE472998T1 (de) | Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| ECSP066559A (enExample) | ||
| EP1965827A4 (en) | TREATMENT OF CONDITIONS RELATED TO DEMYELINATION | |
| ATE474574T1 (de) | Imidazoazephinonverbindungen | |
| EA200801244A1 (ru) | Применение sdf-1 для лечения и/или профилактики неврологических заболеваний | |
| EA200702336A1 (ru) | ПРИМЕНЕНИЕ 24-норУДХК | |
| EA201070496A1 (ru) | УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ | |
| EA201070494A1 (ru) | МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ | |
| NI201000067A (es) | Intermediarios de gsm. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |